## **Desbac**

(Cefpodoxime Proxetil USP Capsule/Suspension)

Presentation:

Desbac Capsule: Each capsule contains Cefpodoxime Proxetil USP 130 mg equivalent to Cefpodoxime 100 mg.

Desbac Suspension: Each 5 ml reconstituted suspension contains Cefpodoxime Proxetil USP equivalent to Cefpodoxime 40 mg. Indications:

Cefpodoxime is indicated for the treatment of the following diseases: Upper respiratory tract infections: Acute otitis media, Sinusitis, Pharyngitis and Tonsillitis

Lower respiratory tract infections : Acute community-acquired pneumonia, Acute

Lower respiratory tract infections: Acute community-acquired pneumonia, Acute bacterial exacerbation of chronic bronchitis
Upper & lower urinary tract infections: Cystitis, Pyelonephritis
Skin & soft tissue infections: Abscesses, Cellulitis, Infected wounds, Furuncles, Folliculitis, Paronychia, Carbuncles and Ulcers
Sexually transmitted diseases: Acute uncomplicated urethral & cervical gonorrhea, Acute ano-rectal infections in women caused by N. gonorrhoeae
Dosage and administration:

Adults (>13 years):

Total fails. Poor furunces.

	Addits (~15 years).				
Type of infections		Total daily	Dose frequency		Duration
	dose		(Days)		
	Acute, community-acquired pneumonia 14		400 mg	200 mg 12 hr	ly
	Acute bacterial exacerbation hrly 10	hitis	400 mg	200 mg 12	
	Uncomplicated gonorrhea dose	n)	200 mg	Single	
	Rectal gonococcal infections (women)		200 mg	Single dose	
	Skin and skin structure	800 mg 400 mg 12 hrly			7-14
	Pharyngitis/tonsillitis	200 mg	100 mg 12 hr		5-10
	Uncomplicated UTI	200 mg	100 mg 12 hr		7
	Children :	200 mg		.,	•
15 days - 6 month : 8mg/kg/day in				n two divided doses	
	6 month - 2 years : 5 ml twice daily				
	3 - 8 years : 10 ml twice daily				
	Above 9 years		12.5 ml or 100 mg capsule twice daily.		
	Contraindications :	•	12.0 1111 01 10	o mg oapouic	twice daily.
	Cefpodoxime proxetil is	contraindicate	d in nationte	with a know	n alleray to
	ceibogovinie bioxeni is	Juliuaniulale	u iii palieiils	WILLI & KITOW	ii alieigy lu

Cefpodoxime or to the Cephalosporin group of antibiotics.

Precautions:

Precautions:
The total daily dose of Cefpodoxime proxetil should be reduced in patients with transient or persistent reduction in urinary output due to renal insufficiency. Cefpodoxime should be administered with caution to patients receiving concurrent treatment with potent diuretics. As with other broad-spectrum antibiotics, prolonged

treatment with potent diuretics. As with other broad-spectrum antibiotics, prolonged use of Cefpodoxime proxetil may result in overgrowth of non-susceptible organisms. Repeated evaluation of the patient's condition is essential.

Use in pregnancy and lactation:
Cefpodoxime was neither teratogenic nor embryocidal in animal trial. There is, however, no adequate and well-controlled study of Cefpodoxime proxetil use in pregnant women. The drug should be used during pregnancy only if clearly needed. As Cefpodoxime is excreted in human milk, a decision should be made whether to discontinue breast-feeding or to discontinue the drug.

Side-affects:

whether to discontinue breast-reeding or to discontinue the drug.

Side-effects:

Cefpodoxime is generally well tolerated. Possible side effects include gastrointestinal disorders such as diarrhoea, nausea, vomiting, abdominal pain, rash, urticaria and itching. Occasional cases have been reported of headaches, dizziness, tinnitus, parethesia, asthenia, and malaise.

Drug interactions:

Artacids: Concomitant administration of high doses of antacids (sodium

Drug interactions:

Antacids: Concomitant administration of high doses of antacids (sodium bicarbonate and aluminium hydroxide) or H2 blockers reduces peak plasma level by 24% to 42% and the extent of absorption by 27% to 32%, respectively. Probenecid: Renal excretion of Cetpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak Cefpodoxime levels. Nephrotoxic drugs: Close monitoring of renal function is advised when Cefpodoxime proxetil is administered concomitantly with compounds of known nephrotoxic potential.

Commercial Pack:

Desbac Capsule: Each box contains 3 alu-alu blister strips of 4 Capsules.

Desbac Suspension: Each bottle contains cefpodoxime proxetil powder to be reconstituted into 50 ml suspension.

